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Both lymphoid and myeloid cells express Fc receptors (FcRs). Low-affinity FcRs engage 
circulating immune complexes, which results in the cellular activation and pr o-inflammatory 
cytokine production. FcRs participate in the internalization, transport, and/or recycling 
of antibodies and antigens. Cytosolic FcRs also route these proteins to proteasomes 
and antigen-presentation pathways. Non-activated CD4+ T-cells do not express FcRs. 
Once activated, naive CD4+ T-cells express FcγRIIIa, which, upon IC ligation, provide 
a costimulatory signal for the differentiation of these cells into effector cell population. 
FcγRIIIa present on CD4+ T-cell membrane could internalize nucleic acid-containing ICs 
and elicit a cross-talk with toll-like receptors. FcγRIIIa common γ-chain forms a heterod-
imer with the ζ-chain of T-cell receptor complex, suggesting a synergistic role for these 
receptors. This review first summarizes our current understanding of FcRs on CD4+ 
T-cells. Thereafter, I will attempt to correlate the findings from the recent literature on 
FcRs and propose a role for these receptors in modulating adaptive immune responses 
via TLR signaling, nucleic acid sensing, and epigenetic changes in CD4+ T-cells.
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iNTRODUCTiON
Immunoglobulin Fc receptors (FcRs) are expressed by many immune cells, and these receptors 
induce many diverse biological functions. Activating- and inhibitory-FcRs are expressed as pairs, 
and they govern the outcome of an immune response. Sandor and Lynch very early on showed that 
T-cell receptor (TCR)-activation results in the induced expression of FcαR, FcμR, and FcϵR in CD4+ 
T-cell clones (1). FcR common γ-chain (FcR-γ) is the ITAM-bearing signaling unit of FcϵRI, FcγRI, 
and FcγRIIIa (2). FcR-γ chain independently supports the complete development of peripheral 
CD4+ T-cells in mice lacking the TCR ζ-chain (3–5). The FcR-γ chain forms a heterodimer with 
the ζ-chain of TCR in CD4+ T-cells. Membrane-FcγRIIIa in these cells can signal using the ζ–ζ 
chain, γ–γ chain homodimers, or ζ–γ chain heterodimers. ζ-chain deletion is not a lethal event for 
CD4+ T-cell development, suggesting an alternative-signaling pathway using the FcR-γ chain. In 
CD4+ T-cells, the FcR-γ chain engages Syk kinase for signaling (6). Syk is a ZAP-70 homolog that 
successfully substitutes for ZAP-70 kinase activity (7). Upon phosphorylation by FcR-γ chain, Syk 
provides a distinct and a stronger signal than the ZAP-70-ζ-chain of TCR complex (7). NK T-cells 
express both the ζ-chain and FcR-γ chain. Both of these signaling proteins associate with FcγRIIIa 
in human NK T-cells; however, in mice, it is only the FcR-γ chain that can associate with FcγRIII 
(8). In NK T-cells, the increased expression of ζ-chain downregulates FcγRIIIa expression (9). These 
studies suggest a regulatory role for these signaling proteins.
Thus far, a role for low-affinity FcRs in CD4+ T-cell responses has not been envisioned, despite a 
number of early studies supporting the presence of these receptors on such cells. Of special interest is 
FiGURe 1 | FcγRiiia–pSyk signal in CD4+ T-cell responses. Activated naive CD4+ T-cells express FcγRIIIa and provide a costimulatory signal. In the absence of 
CD28 costimulation, FcγRIIIa ligation by ICs rescues naive CD4+ T-cells from becoming anergic. These cells show Syk phosphorylation, proliferation, cytoskeletal 
changes, and cytokine production. In the presence of instructive cytokine signals, these cells differentiate into Th1, Th2, and Tfh cells. In GCs, FcRs via ICs will hold 
together Tfh, B-cells, and FDCs forming stable cyto-conjugates.
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how positive costimulation from the FcγRIIIa–pSyk signal could 
alter CD4+ T-cell responses, which, thereby, contribute to toler-
ance breakdown (10, 11). Systemic lupus erythematosus (SLE) 
is a classical autoimmune manifestation and is a good model 
to address these questions since the disease pathology is driven 
by ICs, the primary ligand for FcγRIIIa (12). In addition, SLE is 
associated with a hyperactive T-cell response and the presence 
of autoantibodies that form ICs. Enhanced Th1 and Th17 CD4+ 
T-cell responses are a hallmark of SLE pathology. An indirect role 
for FcRs in the Th1 response has also been proposed (13). ICs are 
present on the membrane of subcapsular sinus macrophages and 
are not phagolysed. Intact ICs are transferred from the plasma 
membrane of antigen-presenting cells (APCs) to the B-cell sur-
face (14–16). In germinal centers (GCs), this makes ICs available 
on APC and B-cell plasma membranes, which are accessible to 
participate directly in the CD4+ T-cell differentiation upon con-
tact with naive CD4+ T-cells (Figure 1). Furthermore, ICs could 
also facilitate formation of cyto-conjugates of CD4+ T-cells with 
other cells expressing FcRs (Figure 1).
The ICs formed by nucleic acids (DNA/RNA) and autoan-
tibodies are pathogenic and trigger TLR signaling and nucleic 
acid sensing (17). In SLE, FcγRIIa internalizes DNA/RNA-ICs in 
plasmacytoid dendritic cells (pDCs), which result in a type 1 IFN 
response, a key driver of SLE disease pathology (18). Even though 
CD4+ T-cells demonstrate TLR signaling in an autoimmune 
response, the mechanisms for the delivery of nucleic acids to 
cytosol are unknown (19, 20). Nucleic acid sensors in innate cells 
drive IFN responses that contribute to autoimmune pathology. 
Data are emerging that link both TLR proteins and DNA sensors 
in the development of CD4+ T-cell effector responses (21–23).
This review will summarize the literature supporting the 
presence of FcRs on CD4+ T-cells, and further makes a case for 
FcγRIIIa–pSyk signaling in the modulation of TLR responses and 
epigenetic changes in the human peripheral CD4+ T-cells.
FcRs ON CD4+ T-CeLLS
The expression of FcRs and their role in CD4+ T-cell-mediated 
adaptive immune responses is controversial. Several groups have 
argued for the lack of low-affinity FcRs on CD4+ T-cells (2, 24). 
This is likely true for non-activated CD4+ T-cells, and these cells 
do not contribute to the disease pathology. However, once acti-
vated, CD4+ T-cells express robust amounts of FcγRIIIa recep-
tors, which is an activation-induced response (10). The activation 
signal that triggers the expression of FγRIIIa in activated cells 
remains unknown. FcγRIIIa was initially reportedly observed 
in a small number of peripheral T-cells in healthy individuals 
(1, 25). Upon binding to FcRs on T-cells, IgM triggers a helper 
function, while ICs binding provides a suppressor function (26). 
Two previous studies have also shown an immunoregulatory role 
for FcR-bearing T-cells in a B-cell-mediated immune response 
(27, 28). A close relationship between FcR expression and cellular 
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activation via the CD3–TCR complex was also documented (28). 
A stringent and narrow window during which FcRs are expressed 
on CD4+ T-cells suggest a possible regulatory role for FcRs in 
adaptive immune responses, and FcR signaling may serve as a 
checkpoint for the development of T effector cells (29). FcR and 
TCR comigrate on the T-cell membrane, suggesting a synergism 
in signaling pathways (1, 30, 31). FcR preferentially colocalizes 
with TCR into the zone of contact formed between B- and T-cells 
during cognate-driven cyto-conjugation (1). In trogocytosis, 
CD4+ T-cells capture both external membrane FcγRIIIa and FcR-
γ chain from the APC expressing FcγR. However, this receptor 
transfer/capture of FcRs by T-cells is not capable of triggering 
a functional response (32). FcγRIIIa-mediated signaling in NK 
T-cells differs from CD4+ T-cells for the production of cytokines, 
which further suggest a divergent role for FcR in CD4+ T-cells 
(33). Sandor and Lynch proposed an “avoidance hypothesis,” 
where a signal in T-cells via FcγRIII might occur in the pres-
ence of antigens and specific antibodies (1). Naive CD4+ T-cells 
activated via ICs ligation of FcγRIIIa show a limited clonal expan-
sion, suggesting a potential contribution from antigenic peptides 
in the ICs. ZAP-70-deficient patients express high levels of Syk, 
which is activated from FcR-γ chain phosphorylation, and it plays 
a distinct role in transducing TCR-mediated signal (34). These 
findings suggest a role for FcγRIIIa signaling via Syk (Figure 1). 
Syk is a key player in CD4+ T-cell activation in SLE and is cur-
rently a therapeutic target (35, 36).
FcRs AND T-CeLL ReSPONSeS
In order for naive CD4+ T-cells to differentiate into effector cells, 
it requires two signals: (1) engagement of TCR by peptide–MHC 
and (2) a cosignal from CD28 upon the ligation by CD80/
CD86 expressed by APCs (37). A third signal from cytokines 
determines whether these cells differentiate into effector Th1, 
Th2, Th17, or regulatory T-cells (Treg) cells. These populations 
maintain and regulate immune homeostasis. Both Th1 and Th17 
cells cause and sustain tissue damage, while Tregs suppress these 
pro-inflammatory cells. Some of the early studies have implicated 
FcRs in the development of suppressor T-cells, now recognized as 
Tregs (26). Thus, it is important to recognize the role of FcγRIIIa 
signal as an additional positive costimulatory signal for CD4+ 
T-cell differentiation.
The secondary adaptive immune responses are fast and robust 
due to rapid expansion of antigen-specific lymphocytes. FcRs 
facilitate these responses by binding to ICs formed by affinity-
matured autoantibodies against autoantigens. In autoimmunity, 
aberrant CD4+ T-cell responses are frequently observed, which 
are accompanied by autoantibody production and the IC forma-
tion. CD3 ligation in the absence of CD28 signal makes naive 
CD4+ T-cells anergic. However, in an autoimmune background, 
naive CD4+ T-cells bypass the CD28 signal requirement for acti-
vation (Figure 1). The underlying mechanism for this activation 
in the absence of CD28 signal is unknown (38). Unlike mice, 
where naive CD4+ T-cells are produced in the thymus, in humans, 
90% of these cells are produced in the periphery from prolifera-
tion (39). Thus, a likely scenario is that, in humans, peripheral 
CD4+CD45RA+ (naive) T-cells have encountered antigen in the 
periphery and hence are different than those observed in mouse 
(39). In multiple sclerosis, differences in naive CD4+ T-cell biol-
ogy, notably of TCR and TLR signaling, have identified patients 
prone to more rapid conversion to secondary progression (40). 
Nano-LC/MS/MS analysis of ICs obtained from SLE patients 
show the presence of 40–250 antigenic peptides. What role these 
IC peptides play in the T-cell activation is not clear (41). Human 
naive CD4+ T-cells activated in vitro by the suboptimal engagement 
of CD3 and costimulated either via CD28 cosignaling or with ICs 
in the presence of non-lytic C5b-9 induce FcγRIIIa expression 
(10). Upon FcγRIIIa engagement by SLE-ICs, these cells produce 
high amounts of IFN-γ and IL-17A (11). The FcγRIII-mediated 
production of IFN-γ is also observed in NK T-cells (9). Several 
mechanisms contribute to the peripheral tolerance breakdown, 
which results in an autoimmune response (42). TCR signal 
strength is one contributor to tolerance breakdown. FcγRIIIa can 
provide an additional positive signal to the TCR for overcoming 
the threshold for tolerance breakdown. Thus, specific inhibition 
of FcγRIIIa signal in CD4+ T-cells provides an attractive thera-
peutic target. Costimulatory pathways influence the outcome of 
T-cell stimulation and are central to the maintenance of immune 
tolerance (42). In the early phase of antigenic challenge from 
pathogens or self-antigens, activating cosignals CD28 and ICOS 
drive an immune expansion. Once the threat from the invading 
pathogens is over, the immune contraction phase is initiated by 
the appearance and expansion of the negative costimulatory pro-
teins PD1 and CTLA4. In an autoimmune response, the FcγRIIIa-
mediated signal, which is an additional positive ITAM signal, can 
drive immune expansion. This will lead to perpetual expansion of 
the immune response such as that observed in autoimmunity. Syk 
phosphorylation is observed in those SLE CD4+ T-cells that also 
produce IFN-γ and IL-17A cytokines (11). FcγRIIIa cosignaling 
drives the differentiation of naive CD4+ T-cells into Th1, Th17, 
and Tfh effector populations (10, 11, 43). The Th17 cells produced 
by an FcγRIIIa signal show markers of terminal differentiation 
that are associated with a pathogenic Th17 population (11). 
In vitro, FcγRIIIa ligation by ICs on naive CD4+ T-cells induces 
ICOS expression both in human and mouse cells. ICOS+CD4+ 
T-cells in SLE patients bind to labeled ICs, suggesting FcγRIIIa 
coexpression (11). However, cells expressing high levels of PD1high 
do not show pSyk, suggesting a role for PD1 in immune contrac-
tion via SHIP2 by dephosphorylating pSyk (11). IC formation is 
observed in several other disease pathologies, including cancer 
and infections. Past and recent literature suggests that FcγRIIIa is 
a crucial player for CD4+ T-cell responses during autoimmunity. 
In future, recognizing the precise mechanism of how FcγRIIIa-
mediated signaling in CD4+ T-cells alters the adaptive immune 
responses will be critical for developing therapies that target 
CD4+ T-cell membrane proteins such as CTLA4, PD1, TLRs, and 
nucleic acid sensors.
CROSS-TALK BeTweeN TLRs AND FcRs
TLR-dependent T-cell activation is observed in autoimmunity 
(19). The presence of FcRs on activated human CD4+ T-cells 
raises the possibility of their coengagement with either TCR 
or TLRs for signaling. Upon ligand engagement, TLRs trigger 
FiGURe 2 | TLR3 on cell membrane with FcγRiiia. Stimulated emission depletion (STED) confocal image of a human CD4+ T-cell activated with plate-bound 
anti-CD3 + ICs + sublytic C5b-9 post 48 h. FcγRIIIa recognized by binding of Alexa Fluor 488-labeled ICs (green) and TLR3 with monoclonal antibody-Alexa Fluor 
594 (red). At the plasma membrane, both proteins colocalized in many spots. IC binding showed cytosolic FcγRIIIa (yellow oval) and on the plasma membrane 
(white arrow). Area amplified from merge shown in yellow rectangular.
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homo-or hetero-dimerization and recruit adaptor proteins to 
activate downstream signaling and transcriptional activation 
(44). Distinct signaling by synergistic engagement and cross-
talk between FcRs and TLRs in immature DCs promote a Th17 
response (45, 46). Such cross-talk between FcRs and TLRs 
expressed by CD4+ T-cells will result in an efficient inflammatory 
immune response and effector T-cell development (47). In B-cells, 
TLRs synergistically engage FcRs, which generate a distinct signal 
(47). Similar signaling events could occur in CD4+ T-cells that 
express FcRs. TLRs bind to pathogen-derived nucleic acids, 
which are taken up by the cells via endocytosis or autophagy 
and transferred to the endolysosomal compartment (48). 
Intracellular pathogenic challenge triggers the generation of Th1 
and CD8+ T-cell responses, which develop from the engagement 
of TLRs by pathogen-associated molecular patterns (PAMPs) 
and produce IL-12, a cytokine that drives IFN-γ production in 
Th1 cells. Both ITAM and MyD88 signaling pathways converge 
after coactivation of FcRs and TLRs, resulting in an appropriate 
inflammatory response. Coactivation of FcRs by ICs and TLRs 
via damage-associated molecular pattern (DAMP) on infiltrating 
myeloid cells in joints of rheumatoid arthritis patients contributes 
to severity of the disease (47). ICs and PAMPs or DAMPs induce 
cross-talk and contribute to both the onset and the exacerbation 
of autoimmune disease (47). The nucleic acid-recognizing TLRs 
(NA-TLRs), also referred to as endosomal TLRs (TLR3, TLR7, 
TLR8, and TLR9), participate in an autoimmune response (20). 
The subcellular partitioning of TLRs, cytosolic vs. membrane, 
discriminates between self and altered non-self DNA and is a key 
mechanism for the development of autoimmunity (49). FcγRIIIa-
mediated signal in CD4+ T-cells upregulates NA-TLRs, which 
then colocalize with FcγRIIIa, and some of these NA-TLRs move 
to the plasma membrane (Figure  2) (11). This is the evidence 
for FcR’s role in modulating TLR signaling in CD4+ T-cells. 
FcγRIIIa-mediated signaling in CD4+ T-cells also upregulates 
MyD88 and HMGB1, the two proteins that are critical for TLR 
signaling and nucleic acid sensing (11). DNA-containing ICs in 
B-cells and pDCs trigger HMGB1-mediated TLR9 activation 
that contributes to autoimmune pathology (50). TLR agonists 
have been used to study TLR signaling events in CD4+ T-cells 
(19). Surprisingly, various CpG oligodeoxynucleotides, a TLR9 
ligand used to study both mouse and human CD4+ T-cells, show 
a costimulatory activity that promotes polarization of different Th 
subsets (51). TLR9-deficient lpr/lpr mice show a selective defect 
in autoantibody production (52). DAMPs induce inflammatory 
T cell responses either directly or indirectly by inducing cytokine 
production from innate cells. TLR signaling overcomes a rate-
limiting chromatin barrier from histone-containing nucleosomes 
that bind DNA, suggesting its role in epigenetic modifications 
(53, 54). IFN-γ cytokine is a key player in TLR signaling and chro-
matin remodeling, and it is produced from FcγRIIIa signaling in 
CD4+ T-cells (10, 53). Observations over the last decade have also 
shown a DC subset-specific expression of PRRs and cytokines 
produced by these cells promote the differentiation of T-cells 
into effector populations (55). Emerging evidence suggests that 
both FcR and TLR signaling trigger CD4+ T-cell-mediated pro-
inflammatory responses. How these signals together influence 
the development of effector T-cells and/or their contribution to 
the expansion of memory T-cell pool will be of interest.
FcRs AND NUCLeiC ACiD SeNSiNG
Nucleic acid-recognizing TLRs primarily reside intracellularly 
in endosomes. This prevents recognition of self nucleic acids 
by the host. Internalization of RNA- or DNA-containing ICs by 
FcγRIIa and subsequent delivery of nucleic acids to endosomes 
results in an inappropriate IFN response (20, 23). Nucleic acid 
reaches the cytosolic compartment either via viral infection or 
by uptake of DNA/RNA-ICs. Thus, FcRs are crucial for the deliv-
ery of nucleic acids to the cytosol, where DNA sensing occurs 
(22). Nucleic acid-sensing pathways are the therapeutic targets 
in both autoimmunity and cancers (56). High mobility group 
box 1 (HMGB1) protein is crucial for the efficient delivery of self 
nucleic acids to TLR-containing endosomes (50, 57). HMGB1 
associates with DNA-ICs and stimulates cytokine production via 
the TLR9–MyD88 pathway in pDCs (50). HMGB1 uses TLR2 
and TLR4 as cellular receptors and engages S100 calcium binding 
protein A12 (RAGE) to produce type 1 IFN (58). The mechanism 
and route for RNA/DNA delivery to endolysosome or to the ER 
in CD4+ T-cells are not yet recognized. Membrane FcγRIIIa on 
activated CD4+ T-cells provides a possible route and mode of 
RNA/DNA-ICs internalization and delivery of the nucleic acids 
to the endosomes (Figure 2).
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Nucleic acids activate immune cells to induce inflammation 
and immunity (22). Both TLRs and retinoic acid-inducible gene 
1 (RIG-1)-like helicases participate in nucleic acid recognition. 
Immune sensing of DNA is observed both in early innate as 
well as late adaptive immune responses (59, 60). Aberrant DNA, 
altered self-DNA, and cyclic dinucleotide sensing by signaling 
proteins in the cytosol trigger DNA-signaling pathways. DNA-
ICs and nucleosomes are closely associated with the development 
of inflammation in SLE. DNA-sensing proteins co-operate with 
TLRs to mount the immune challenge and discriminate against 
damaged DNA. ICs that stimulate B-cells contain DNA that is 
hypomethylated and such ICs modulate T-cell responses (61). 
Members of the DExD/H box helicase family of proteins, such 
as RIG-1, interferon inducible helicase C (IFIH1/MDA5), and 
RIG-1-like receptor (LGP2) recognize cytosolic ssRNA and 
dsRNA and signal through mitochondrial antiviral signaling 
proteins to activate interferon regulatory factor (IRF) 1, IRF3, 
IRF7, and NF-κB. These, in turn, trigger expression of IFN-α and 
other pro-inflammatory cytokines (21). FcγRIIIa engagement by 
ICs in CD4+ T-cells enhances the expression of both IRF3 and 
IRF7. FcγRIIIa expression by CD4+ T-cells opens up the pos-
sibility that the DNA-ICs bind to PHYIN (pyrin and HIN200) 
domain-containing family protein absent in melanoma 2 (AIM2) 
and to apoptosis-related speck protein (ASC), leading to the 
formation of inflammasome-like structures producing IL-1β in 
CD4+ T-cells. IC stimulation of human naive CD4+ T-cells via 
FcγRIIIa induces production of IL-1β (11). Thus, the expression 
of FcγRIIIa on activated CD4+ T-cells could be a crucial partici-
pant in the nucleic acid-signaling pathway.
ePiGeNeTiC CHANGeS iN CD4+ T-CeLLS 
FROM FcγRiiia–Syk SiGNALiNG
Epigenetic modifications are crucial for the differentiation and 
maintenance of CD4+ helper T-cell subsets. Acetylation and 
methylation of histones, which are considered epigenetic marks, 
are observed in SLE pathology. Both ifng and il17a promoters 
show epigenetic marks. Hypomethylation of il4 and il6 promoters 
are associated with disease activity (62). Even though a role for 
epigenetics in the differentiation of CD4+ T-cell helper subsets is 
recognized, what drives these changes is unknown. In particular, it 
will be of interest to examine the mechanisms that drive epigenetic 
changes in the Bcl6 locus. Bcl6 is a transcription factor associated 
with the Tfh lineage that exhibits H3K4me3 marks, suggest-
ing gene upregulation. Those genes that cause modification to 
histones and DNA show marked upregulation by FγRIIIa–pSyk 
signaling in naive CD4+ T-cells. This signal also drives the differ-
entiation of Th1, Th17, and Tfh subsets (11, 43, 63). Our analysis 
of five donors for the genes associated with epigenetic chromatin 
modification showed a correlation among DNA (cytosine-5-)-
methyltransferase 1 (DNMT1), retinoblastoma-binding protein 
7 (RBBP7), chromodomain helicase DNA-binding protein 4 
(CHD4), and methyl-CpG-binding domain protein 2 (MBD2) 
(63). These enzymes are part of a histone deacetylase complex and 
are upregulated by the FcγRIIIa–pSyk signal. The SET domain-
containing lysine methyltransferases (SETD)-7 and SETD-2, 
which generate an H3K4me1, and SETD-1 that generates a H3K9 
methyl mark, were also significantly upregulated by FcγRIIIa–
pSyk cosignaling compared to the canonical CD28 cosignal (63). 
H3K4me1 is enriched at poised or active genes and shown to be 
a marker of active enhancers in combination with H3K27ac and 
p300 binding (64). H3K27 hypomethylation and H3K18 hyper-
methylation are observed in activated naive CD4+ T cells and in 
SLE T-cells (65). These findings suggest that by upregulating DNA 
modification enzymes, the FcγRIIIa–pSyk signal causes epigenetic 
changes in human CD4+ T-cells. In Th1 cells, the ifng locus shows 
permissive histone modifications and DNA demethylation (66). 
In the promoter regions of 14,495 genes in SLE, CD4+ T cells, 
236 were hypomethylated and 105 were hypermethylated (67). 
A profound hypomethylation of genes regulated by type I IFN 
was observed in genome-wide DNA methylation analysis (68). 
Methylation changes in SLE persist beyond flares for several 
months (68). SLE patients demonstrate the elevated presence of 
complement-opsonized ICs that engage membrane FcγRIIIa. 
Thus, it is plausible that the FcγRIIIa–pSyk signal in CD4+ T-cells 
contributes to the modifications observed in the ifng and il17a 
promoters. DNA methyltransferase, Dnmt3a, establishes a geneti-
cally silent chromatin structure at the regulatory region of ifng 
locus by methylating DNA. It has been proposed that methylation 
at −53 CpG by Dnmt3a suppresses IFN-γ transcription during 
Th2 development (69). FcγRIIIa–pSyk signaling suppresses 
Dnmt3a expression compared to CD28 signaling in CD4+ T-cells. 
This −53 region is also the preferred binding site for activation 
transcription factor (ATF)2. In our study, the FcγRIIIa–Syk signal 
significantly upregulated the ATF2 gene expression, suggesting 
a possible role in increased IFN-γ production (11). KAT6A is 
another lysine-transferase that was significantly upregulated by 
FcγRIIIa–pSyk signaling. This gene is suggested to act as a coac-
tivator of RUNX1, which drives Th17 differentiation. Children 
with a mutation in  KAT6A show developmental disorders and 
cognitive defects (www.Chloekat6a.org). Decrease in DNMT 
expression results in hypomethylation of promoters of SLE-
associated genes, which drives their overexpression. A positive 
correlation with DNMT1 and MBD2 expression is observed with 
disease activity in SLE patients (70, 71). Epigenetic changes not 
only regulate the differentiation of CD4+ T-cells but also TLR 
signaling (72). CD4+ T cells express TLR4 (not a DNA sensor), 
which drives epigenetic regulation of the TNF-α promoter (73). 
Also, the pan-histone deacetylase inhibitor LBH589 represses 
cytokines IL-6, IL-10, IL-12, and IL-23 (74). Treatment of CD4+ 
T-cells with demethylating agents (hydrazine, procainamide, and 
5-AzaC) renders them autoreactive. Adoptive transfer of such 
cells in mice causes them to produce anti-dsDNA antibodies and 
develop IC glomerulonephritis (75). These studies document a 
role for epigenetics in autoimmune pathology and data from our 
laboratory showed modulation of several enzymes that cause epi-
genetic modifications by FcγRIIIa–pSyk signaling (63). It will be 
important to further investigate these mechanisms to understand 
and enhance the efficacy of demethylating agents for SLE therapy.
CONCLUDiNG ReMARKS
Even though earlier studies documented the presence of 
low-affinity FcRs on CD4+ T-cells, neglect in examining the 
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contribution of these receptors in CD4+ T-cell responses over the 
past two decades has hampered progress in establishing the con-
tribution of FcRs to adaptive immune responses. Emerging data 
reconfirm some of the earlier findings that activated CD4+ T-cells 
not only express FcRs, but signaling via these receptors modulates 
adaptive immune responses. Engagement of FcRs by the ligand 
contributes to the development of CD4+ effector T-cell responses. 
Low-affinity FcRs are critical for innate immune responses, and 
their presence on CD4+ T-cells, cells of adaptive immunity, sug-
gests their critical role in adaptive immunity. Cross-linking by 
complexed-Ig triggers proliferation of FcγRIIIa-bearing CD4+ 
T-cells via receptor dimerization. The internalization of RNA/
DNA-ICs by FcγRIIIa+CD4+ T-cells by engaging TLRs triggers 
signaling via DNA sensors. Whether these signaling events 
contribute to the development of IFN signature and plasma 
cell development will be important to understand the underly-
ing mechanism of autoimmune pathology. It will be of further 
significant interest to explore whether induced expression of TLR 
proteins by FcγRIIIa signaling generate a cross-talk with TLRs 
and enhance nucleic acid sensing. How these signals influence 
the fate of effector T-cells and contribute to the central memory 
pool is an important question. On memory recall, such cells will 
be able to provide B-cell help and drive them to differentiate 
into plasma B-cells. Understanding of the interactions among 
FcRs, TLRs, and/or TCR will assist in explaining autoimmune 
pathology.
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